Drug Profile
Pachymatismin
Latest Information Update: 14 Feb 2000
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Glycoproteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Feb 2000 No-Development-Reported for Cancer in France (Unknown route)
- 18 Dec 1996 New profile
- 18 Dec 1996 Preclinical development for Cancer in France (Unknown route)